Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma

Figure 1

Frequency of antigen expression in patients newly diagnosed with multiple myeloma. CD56 and CD13 were the most common aberrant antigens in neoplastic plasma cells (56% and 53%, resp.), followed by CD33, CD117, and CD20. CD13 and CD33, the traditional myeloid markers, showed relatively high prevalence.